Mercer Global Advisors
ABOS icon

Mercer Global Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

Mercer Global Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$534 Buy
+200
New +$494 ﹤0.01% 5822

Other funds holding ABOS

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Mercer Global Advisors's ABOS Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Acumen Pharmaceuticals (ABOS) in Q2 2026: 200 shares worth $534. The stake represents ﹤0.01% of the portfolio and ranks #5822 among its holdings.

63 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Mercer Global Advisors held 200 shares of Acumen Pharmaceuticals worth $534 as of Q2 2026.
  • Acumen Pharmaceuticals was a new Mercer Global Advisors position in Q2 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5822 holding.
  • 63 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.